415 results on '"Masszi, T."'
Search Results
2. Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease
3. The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy
4. P615: BCL2 RESISTANCE MUTATIONS IN A REAL-WORLD COHORT OF PATIENTS WITH VENETOCLAX-TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA
5. P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
6. Supplement to: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.
7. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
8. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group
9. Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population
10. Outcome of 29 myeloablative allogenic hematopoietic cell transplantations in multiple myeloma: AB99
11. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
12. The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantationassociated thrombotic microangiopathy
13. Accelerated clearance alone explains ultra‐large multimers in von Willebrand disease Vicenza
14. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
15. Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients
16. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA
17. An Alu‐mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary
18. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia
19. Haematopoietic stem cell transplantation in children in eastern European countries 1985–2004: development, recent activity and role of the EBMT/ESH Outreach Programme
20. Heat-sensitization allows the detection of anti-FVIII antibodies in patients with acquired hemophilia, who have a negative Bethesda assay: PB 4.55–3
21. Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation
22. Plerixafor might overcome the detrimental effect of previous autologous stem cell transplantation on haematopoietic stem cell mobilization in myeloma patients: P1078
23. Plerixafor boost in association with chemotherapy based mobilization. Comparison with mobilization without chemotherapy: P1079
24. Tacrolimus and short courses sirolimus graft-versus-host disease prophylaxis regimen for HLA-identical sibling myeloablative peripheral blood stem cell transplantation: P483
25. Treatment of hyperacute graft-versus-host disease with early extracorporal photopheresis and standard dose of methylprednisolone after volunteer unrelated donor allograft: P482
26. Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: 0117
27. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study: A166
28. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey
29. Successful allogeneic peripheral haematopoietic stem cell transplantation for myelodysplastic syndrome associated Behçet's disease: case report
30. The importance of chronic graft-versus-host disease after myeloablative stem cell transplantation for imatinib resistant advanced phase CML
31. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia
32. Insights on Multiple Myeloma Treatment Strategies
33. CIDP cured by allogeneic hematopoietic stem cell transplantation
34. Zevalin therapy of a non-Hodgkin relapsed lymphoma patient following an autologous peripheral stem cell transplantation
35. Remarkable reduction of acute GvHD and infectious complications after reduced-intensity conditioning and low-dose (30 mg) campath-1H
36. Examination of oropharyngeal Candida inconspicua isolates in stem cell transplant patients
37. How to use UVAR XTS photopheresis system in small weight children
38. Life-threatening hepatic complications in myeloablative stem cell transplantation in advanced phase CML patients receiving imatinib immediately prior to conditioning
39. Successful peripheral stem cell mobilisation and effective in vivo purging with gemtuzumab ozogamicin in a patient with secondary acute myeloid leukaemia
40. Serum α2-HS glycoprotein concentration in patients with hematological malignancies: A follow-up study
41. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination
42. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
43. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
44. PF409 DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS
45. PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK
46. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
47. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
48. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment
49. Randomised phase III study of alisertib or investigator's choice (selected singe agent) in patients with relapsed or refractory peripheral T-cell lymphoma
50. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.